Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2402234 in Recurrent IDH-Mutant Glioma
NCT05061251Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of orludodstat in glioma, sponsored by UT Southwestern Medical Center. Primary endpoint: Biological activity of BAY 2402234 at 3 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
orludodstat
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05061251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061251.